Metsera is a clinical-stage biopharmaceutical company at the forefront of revolutionizing obesity treatment through innovative, next-generation therapies. Founded in 2022, Metsera has rapidly established itself as a leader in the development of nutrient-stimulated hormone (NuSH) therapeutics, aiming to reduce the physical, emotional, and economic burdens of obesity—a global health challenge affecting hundreds of millions. The company’s mission centers on engineering, developing, and commercializing potent, ultra-long-acting, and scalable medicines that are both injectable and oral, designed to make treatment more accessible, convenient, and effective for patients. Metsera’s approach is rooted in a proprietary peptide engineering platform, which enables the creation of therapies with best-in-class performance, improved tolerability, and enhanced scalability. Its portfolio includes multiple candidates that promise to lower barriers to adoption and long-term use, with the goal of enabling oral therapies that deliver results comparable to injectables. By integrating agile translational science, efficient clinical development, and large-scale manufacturing, Metsera is redefining how obesity medicines are developed and delivered. A key achievement for Metsera is its acquisition by Pfizer, announced in September 2025. This strategic move positions Metsera’s innovative pipeline to benefit from Pfizer’s global clinical, regulatory, manufacturing, and commercial capabilities, accelerating the potential for widespread impact. The acquisition underscores Metsera’s reputation as a category leader in obesity therapeutics and highlights its promise to transform the lives of millions. Notably, Metsera’s vision extends beyond treatment to empowering sustainable weight loss and maintenance, making it a standout in the biotech sector for both its scientific innovation and its commitment to scalable, patient-centric solutions.